statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Day One Biopharmaceuticals (NASDAQ:DAWN  Get Free Report)s stock had its overweight rating reiterated by equities research analysts at Piper Sandler in a research report...

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by Piper Sandler

Day One Biopharmaceuticals (NASDAQ:DAWN  Get Free Report)s stock had its overweight rating reaffirmed by equities research analysts at Piper Sandler in a research note...

Day One Biopharmaceuticals (NASDAQ:DAWN) Earns "Overweight" Rating from Piper Sandler

Investors eyeing a purchase of Day One Biopharmaceuticals Inc (DAWN) stock, but cautious about paying the going market price of 15.12/share, might benefit from considering selling puts among the...

Commit To Purchase Day One Biopharmaceuticals At $12.50, Earn 52.8% Annualized Using Options

Alps Advisors Inc. raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN  Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent filing...

Alps Advisors Inc. Boosts Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN  Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $16.68, but opened at $16.34. Day One...

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down to $16.68

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN  Free Report)  Equities researchers at Capital One Financial issued their FY2028 earnings per share (EPS) estimates for shares of Day One...

Capital One Financial Weighs in on Day One Biopharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:DAWN)

Day One Biopharmaceuticals reports Q4 results...

Day One Biopharmaceuticals reports Q4 results

PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023...

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Barclays PLC decreased its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN  Free Report) by 8.7% in the third quarter, according to its most recent 13F filing with the Securities and...

Barclays PLC Sells 12,521 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects...

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Volume	4.62M
52-Wk High	$17.85
52-Wk Low	$9.67

DAWN Day One Biopharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals